DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo
Market statusData NSENot investment advice
SUDARSHAN PHARMA IND

SUDARSHAN PHARMA IND Latest Share Price (SUDARSHAN)

₹32.71
0.01+0.03%
Overall Score53/100
Day range32
₹32.71
34
52-week31
₹32.71
39
Above low+5.5%
Below high16.8%
Range position21%
Open32.71
Prev Close32.70
Bid32.69100
Ask32.74100

TODAY IN ONE LINE

SUDARSHAN is little changed at ₹32.71 — a quiet consolidation day, supported by recent strong earnings.

it trades at a P/E of 28.27. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume93.0K−13%vs 20D avg
Price Band—
Lower Band0
Upper Band0
Tick Size0.01
Daily Volatility0.00%
Annualised Vol0.00%
Market Cap—
Promoter57.81%
Face Value₹1
Fwd P/E—
PEG—
EV/EBITDA—
P/S—
ROA—
Beta—
Div Payout—
THE STOCK SCORE
Overall Score53/100
Updated 28 Oct

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

SUDARSHAN PHARMA IND flags & news 

Key strengths, potential risks, and recent updates.

✅ 5 green flags🚩 1 red flag

Green Flags

  • ●Quarterly OutperformanceLatest quarter Sales up 24.4% and Profit up 38.7%
  • ●High Promoter HoldingPromoters hold 57.8% skin-in-the-game
  • ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
  • ●FII AccumulationFII holding increased by 2.57% QoQ
  • ●Zero Pledge RiskNo recent active promoter pledging found

Red Flags

Latest SUDARSHAN PHARMA IND News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

13 NOV 2026
corporate
Investor Presentation - Sudarshan Pharma Industries Limited has informed the Exchange about Investor Presentation
View PDF
13 NOV 2026
corporate
Investor Presentation - Sudarshan Pharma Industries Limited has informed the Exchange about Investor Presentation
View PDF
12 NOV 2026
corporate
Resignation of Director/KMP/SMP - Sudarshan Pharma Industries Limited has informed the Exchange about Resignation of Director/KMP/SMP
View PDF
09 NOV 2026
corporate
Resignation - Sudarshan Pharma Industries Limited has informed the Exchange regarding Resignation of Mr Nirav Shah...
View PDF
09 NOV 2026
corporate
Resignation of Director/KMP/SMP - Sudarshan Pharma Industries Limited has informed the Exchange about Resignation of Director/KMP/SMP
View PDF
🔒Prime: full history + alerts on this stock
Valuation

SUDARSHAN PHARMA IND valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for SUDARSHAN PHARMA IND, framed against the sector median so the premium or discount is obvious at a glance.

SUDARSHAN PHARMA IND trades at a P/E of 28.27× and P/B of 4.11×.

Key MetricsMarket + reported · 13 Nov 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
—
P/E Ratio
28.27
P/B Ratio
4.11
EPS
₹0.32
Profitability

Profitability

ROE
—
ROCE
—
Net Margin
—
Op Margin
—
Growth

Growth

EPS YoY
—
Revenue YoY
—
Qtr Sales
24.4%
Qtr Profit
38.7%
Financial Health

Financial Health

Debt / Equity
—
Book Value
₹6.14
Div Yield
—
Promoter Holding
57.81%
Technicals

SUDARSHAN PHARMA IND technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SUDARSHAN PHARMA IND — derived from the latest tape, not yesterday's close.

SUDARSHAN PHARMA IND last traded at ₹32.71 with an intraday range of ₹31.73–₹33.86 — latest indicator, pivot and CPR signals below.

Last updated: 16 November 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹32.71
LevelPrice (₹)Distance% Δ
R438.06+5.35+16.37%
R335.93+3.22+9.85%
R234.90+2.19+6.69%
R133.80+1.09+3.34%
PIVOT32.770.060.17%
CURRENT32.71——
S131.67-1.04-3.17%
S230.64-2.07-6.34%
S329.54-3.17-9.68%
S427.41-5.30-16.19%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 32.74P: 32.77TC: 32.80
R1
R2
R3
R4
indicator
LTP: 32.71
PDH: 33.98
PDL: 32.01
● Market Sentiment

SUDARSHAN is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Average

● Opening Range

Day's range: ₹31.73–₹33.86

● Price Position

Trading Inside opening range

Financials

SUDARSHAN PHARMA IND financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for SUDARSHAN PHARMA IND — consolidated or standalone — with margins, YoY growth and key ratios inline.

SUDARSHAN PHARMA IND reports its full P&L, balance sheet, cash flow and ratios on this page — current reported EPS of ₹0.32.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricApr 2025Apr 2026
Revenue from Operations505
703
▲ 39.2%
Sales Growth YoY %Derived—
39.21%
Other Income3
9
▲ 246.0%
Total Income508
712
▲ 40.2%
440
619
▲ 40.8%
Gross ProfitDerived65
84
▲ 28.2%
Gross Margin %Derived12.93%
11.90%
25
32
▲ 27.6%
EBITDA (Operating Profit)Derived40
51
▲ 28.5%
OPM %Derived7.90%
7.30%
15
29
▲ 94.3%
Profit Before Tax (PBT)22
31
▲ 41.2%
6
7
▲ 24.7%
Effective Tax %Derived26.57%
23.47%
Total Profit for Period16
23
▲ 47.1%
Less: Non-controlling Interests—
0
Net Profit (Owner's PAT)Derived16
23
▲ 46.7%
Net Profit Margin %Derived3.14%
3.31%
PAT Growth YoY %Derived—
46.71%
Earnings Per Share (EPS ₹)0.66
0.97
▲ 47.0%
Diluted Shares Outstanding (Cr)24
24
▲ 0.0%
Other Comprehensive Income (Net of Tax)—
0
Total Expenses (incl. D&A & Interest)486
681
▲ 40.2%
Material Cost % of RevenueDerived1.77%
5.56%
Employee Cost % of RevenueDerived0.97%
1.06%
Other Cost % of RevenueDerived4.05%
3.55%
Interest Coverage (x)Derived2.39x
1.85x
Sales CAGR · 3Y
+15.1%
PAT CAGR · 3Y
+49.1%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

SUDARSHAN PHARMA IND segment analysis : revenue and profit mix.

Disclosed business segments at SUDARSHAN PHARMA IND with their share of revenue and profit, switchable between consolidated and standalone reporting.

SUDARSHAN PHARMA IND discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for SUDARSHAN PHARMA IND.

Our AI distills the core fundamental drivers supporting SUDARSHAN PHARMA IND, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

No weaknesses or threats on record.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 37 would leave less room for earnings disappointment.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

Shareholding

SUDARSHAN PHARMA IND shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in SUDARSHAN PHARMA IND — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

Promoters57.81%↑0.42%
Public20.19%↓2.42%
FII21.95%↑2.00%
Govt0.05%

Ownership Distribution

Promoters
57.81%
Retail & Public
20.19%
Foreign Institutions
21.95%
Government Holdings
0.05%

Category Trends

Foreign Institutions Breakdown
Total Holding: 21.95%
Net Change: +2.00%
Category Total21.95%
Total Holding21.95%
Net Change+2.00%
Not Fully Disclosed

⚠️Partial Disclosure Notice

Individual institutions below total 18.97%, but category aggregate is 21.95%. Some institutions may not be disclosed by the company as per regulatory requirements.

Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod
Century India Opportunity Fund Pc
3.18%
0.25%
-0.25%
Sep 2026
EMINENCE GLOBAL FUND PCC- EUBILIA CAPITAL PARTNERS
2.77%
0.75%
+0.75%
Sep 2026
EBISU GLOBAL OPPORTUNITIES FUND LIMITED
1.93%
0.06%
-0.06%
Sep 2026
Unbounded Opportunities Fund SPC –Alpha Investments SP
1.89%
1.89%
+1.89%
Sep 2026
NORTH STAR OPPORTUNITIES FUND VCC-BULL VALUE INCOR
1.65%
0.06%
-0.06%
Sep 2026
Coeus Global Opportunities Fund
1.65%
0.09%
-0.09%
Sep 2026
MINERVA VENTURES FUND
1.57%
1.57%
+1.57%
Sep 2026
Bridge India Fund
1.56%
0.09%
-0.09%
Sep 2026
NEXPACT LIMITED
1.51%
0.39%
-0.39%
Sep 2026
Pine Oak Global Fund
1.26%
1.26%
+1.26%
Sep 2026
RADIANT GLOBAL FUND-CLASS B PARTICIPATING SHARES
0.00%
0.00%
0.00%
Sep 2026
SAINT CAPITAL FUND
0.00%
0.00%
0.00%
Sep 2026
Multitude Growth Funds Limited
0.00%
4.86%
-4.86%
Sep 2026
Peers

SUDARSHAN PHARMA IND peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SUDARSHAN PHARMA IND is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
BAYER CROPSCIENCE
₹1549153.91 Lakh Cr
Best Profit Growth
ISHAN DYES N CHEMICALS L
3909.87 %
Highest Dividend Yield
BAYER CROPSCIENCE
4.35 %

Peer Comparison

Company Name
09 · Chart Patterns

SUDARSHAN PHARMA IND chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for SUDARSHAN PHARMA IND — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

SUDARSHAN PHARMA IND delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for SUDARSHAN PHARMA IND over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in SUDARSHAN PHARMA IND stood at 55.2% of traded volume, against a 20-day average of 52.9%.

Avg Delivery (13D)52.9%+2.3 ppt latest vs avg
Highest Delivery69.8%on 28 Oct
Avg Volume (13D)1.07 L13-day run-rate
Conviction Trend↓ Weakening+2.3 ppt latest read
Volume & Delivery · last 13 sessions
Exchange Filings & Investor Updates

SUDARSHAN PHARMA IND announcements: results, concalls, ratings, M&A.

Filings SUDARSHAN PHARMA IND sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

SUDARSHAN PHARMA IND files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 10 documents below.

  1. 13 Nov 2026Investor PresentationView PDF

    Investor Presentation

    Sudarshan Pharma Industries Limited has informed the Exchange about Investor Presentation

  2. 12 Nov 2026Resignation of Director/KMP/SMPView PDF

    Resignation of Director/KMP/SMP

    Sudarshan Pharma Industries Limited has informed the Exchange about Resignation of Director/KMP/SMP

  3. 09 Nov 2026ResignationView PDF

    Resignation

    Sudarshan Pharma Industries Limited has informed the Exchange regarding Resignation of Mr Nirav Shah as Company Secretary & Compliance Officer of the…

  4. 09 Nov 2026Resignation of Director/KMP/SMPView PDF

    Resignation of Director/KMP/SMP

    Sudarshan Pharma Industries Limited has informed the Exchange about Resignation of Director/KMP/SMP

  5. 07 Nov 2026General UpdatesView PDF

    General Updates

    Sudarshan Pharma Industries Limited has informed the Exchange about General Updates

§ 10b · Reports & Decks

Investor decks & rating reports.

Corporate Actions

SUDARSHAN PHARMA IND dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue SUDARSHAN PHARMA IND has declared, sequenced by announce and record date.

SUDARSHAN PHARMA IND corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

About the Company

About SUDARSHAN PHARMA IND: business, sector, key facts.

What SUDARSHAN PHARMA IND does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

SUDARSHAN PHARMA IND is a listed Indian equity.

SUDARSHAN
Listed Equity

SUDARSHAN PHARMA IND

company facts
Employees—
Sector—
Headquarters—
Market Cap—
Listed OnNSE · BSE
§ ∞ · Plainly Answered

Questions investors ask about SUDARSHAN PHARMA IND (SUDARSHAN).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of SUDARSHAN PHARMA IND (SUDARSHAN)?

The current share price of SUDARSHAN PHARMA IND (SUDARSHAN) is ₹32.71. Today, the stock has gained by ₹0.01 (0.03%), trading in a range of ₹31.73 to ₹33.86. The stock opened at ₹32.71 with a trading volume of 92,985 shares.

02Is SUDARSHAN PHARMA IND stock a good investment for long-term?

SUDARSHAN PHARMA IND can be considered for long-term investment based on several factors. The company has a market capitalization of ₹0, P/E ratio of 28.27, ROE of 0%, and ROCE of 0%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of SUDARSHAN PHARMA IND stock?

The 52-week high price of SUDARSHAN PHARMA IND (SUDARSHAN) is ₹39.30, while the 52-week low is ₹31.01. Currently trading at ₹32.71, the stock is 5.48% above its 52-week low and 16.77% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy SUDARSHAN PHARMA IND stock at the current price?

Whether to buy SUDARSHAN PHARMA IND stock at ₹32.71 depends on multiple factors. The stock is currently trading with a P/E ratio of 28.27 and P/B ratio of 4.11. Today's performance shows a gain of 0.03%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of SUDARSHAN PHARMA IND and when is the next dividend?

SUDARSHAN PHARMA IND offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹32.71, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06How is SUDARSHAN PHARMA IND stock performing today in the market?

SUDARSHAN PHARMA IND stock opened at ₹32.71 and is currently trading at ₹32.71, showing a gain of ₹0.01 (0.03%). The intraday high is ₹33.86 and low is ₹31.73. The trading volume stands at 92,985 shares, indicating moderate market participation today.

07What is the P/E ratio of SUDARSHAN PHARMA IND and what does it indicate?

SUDARSHAN PHARMA IND has a Price-to-Earnings (P/E) ratio of 28.27, which means investors are willing to pay 28.27 for every ₹1 of earnings. With an EPS of ₹0.32, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

08What is the market capitalization of SUDARSHAN PHARMA IND?

SUDARSHAN PHARMA IND has a market capitalization of ₹0, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹32.71) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.

Disclaimer

The data, ratios and commentary about SUDARSHAN PHARMA IND (SUDARSHAN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.